A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino)methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat

被引:343
作者
Honore, Prisca [1 ]
Donnelly-Roberts, Diana [1 ]
Namovic, Marian T. [1 ]
Hsieh, Gin [1 ]
Zhu, Chang Z. [1 ]
Mikusa, Joe P. [1 ]
Hernandez, Gricelda [1 ]
Zhong, Chengmin [1 ]
Gauvin, Donna M. [1 ]
Chandran, Prasant [1 ]
Harris, Richard [1 ]
Medrano, Arturo Perez [1 ]
Carroll, William [1 ]
Marsh, Kennan [1 ]
Sullivan, James P. [1 ]
Faltynek, Connie R. [1 ]
Jarvis, Michael F. [1 ]
机构
[1] Abbott Labs, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA
关键词
D O I
10.1124/jpet.106.111559
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
ATP-sensitive P2X(7) receptors are localized on cells of immunological origin including glial cells in the central nervous system. Activation of P2X7 receptors leads to rapid changes in intracellular calcium concentrations, release of the proinflammatory cytokine interleukin-1 beta(IL-1 beta), and following prolonged agonist exposure, cytolytic plasma membrane pore formation. P2X(7) knockout mice show reduced inflammation as well as decreased nociceptive sensitivity following peripheral nerve injury. A-740003 (N-(1-{[(cyanoimino)(5-quinolinylamino) methyl] amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl) acetamide) is a novel competitive antagonist of P2X(7) receptors (IC50 values = 40 nM for human and 18 nM for rat) as measured by agonist-stimulated changes in intracellular calcium concentrations. A- 740003 showed weak or no activity (IC50 > 10 mu M) at other P2 receptors and an array of other neurotransmitter and peptide receptors, ion channels, reuptake sites, and enzymes. A-740003 potently blocked agonist-evoked IL-1 beta release (IC50 = 156 nM) and pore formation (IC50 = 92 nM) in differentiated human THP-1 cells. Systemic administration of A-740003 produced dose-dependent antinociception in a spinal nerve ligation model (ED50 = 19 mg/kg i.p.) in the rat. A-740003 also attenuated tactile allodynia in two other models of neuropathic pain, chronic constriction injury of the sciatic nerve and vincristine-induced neuropathy. In addition, A-740003 effectively reduced thermal hyperalgesia observed following intraplantar administration of carrageenan or complete Freund's adjuvant (ED50 = 38-54 mg/kg i.p.). A-740003 was ineffective in attenuating acute thermal nociception in normal rats and did not alter motor performance at analgesic doses. These data demonstrate that selective blockade of P2X(7) receptors in vivo produces significant antinociception in animal models of neuropathic and inflammatory pain.
引用
收藏
页码:1376 / 1385
页数:10
相关论文
共 56 条
  • [1] Emerging challenges of assigning P2X7 receptor function and immunoreactivity in neurons
    Anderson, CM
    Nedergaard, M
    [J]. TRENDS IN NEUROSCIENCES, 2006, 29 (05) : 257 - 262
  • [2] Armstrong JN, 2002, J NEUROSCI, V22, P5938
  • [3] Synthesis and biological activity of N-arylpiperazine-modified analogues of KN-62, a potent antagonist of the purinergic P2X7 receptor
    Baraldi, PG
    Nuñez, MD
    Morelli, A
    Falzoni, S
    Di Virgilio, F
    Romagnoli, R
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (08) : 1318 - 1329
  • [4] Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms
    Beigi, RD
    Kertesy, SB
    Aquilina, G
    Dubyak, GR
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2003, 140 (03) : 507 - 519
  • [5] A PERIPHERAL MONONEUROPATHY IN RAT THAT PRODUCES DISORDERS OF PAIN SENSATION LIKE THOSE SEEN IN MAN
    BENNETT, GJ
    XIE, YK
    [J]. PAIN, 1988, 33 (01) : 87 - 107
  • [6] Pharmacological characterization of recombinant human and rat P2X receptor subtypes
    Bianchi, BR
    Lynch, KJ
    Touma, E
    Niforatos, W
    Burgard, EC
    Alexander, KM
    Park, HS
    Yu, HX
    Metzger, R
    Kowaluk, E
    Jarvis, MF
    van Biesen, T
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 376 (1-2) : 127 - 138
  • [7] Bianchi M, 1998, J NEUROSCI RES, V53, P645, DOI 10.1002/(SICI)1097-4547(19980915)53:6<645::AID-JNR2>3.0.CO
  • [8] 2-5
  • [9] Pathophysiology and therapeutic potential of purinergic signaling
    Burnstock, G
    [J]. PHARMACOLOGICAL REVIEWS, 2006, 58 (01) : 58 - 86
  • [10] Purinergic receptors: Their role in nociception and primary afferent neurotransmission
    Burnstock, G
    Wood, JN
    [J]. CURRENT OPINION IN NEUROBIOLOGY, 1996, 6 (04) : 526 - 532